Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study

John J Laterra, Stuart A Grossman, Kathryn Anne Carson, Glenn J. Lesser, Fred H. Hochberg, Mark R. Gilbert

Research output: Contribution to journalArticle

Abstract

Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance. The safety and benefits of combining inhibitors of angiogenesis and growth factors with cytotoxic therapies in patients with neoplasms of the central nervous system remain unclear. The objectives of this phase 2 study were to determine the safety of administering suramin with standard cranial radiotherapy (RT) and to estimate survival using this approach in patients with newly diagnosed glioblastoma multiforme (GBM). Fifty-five patients with newly diagnosed GBM (Karnofsky performance status ≥60) were enrolled in this multicenter phase 2 study. Patients received suramin by a conventional intermittent fixed-dosing regimen for 1 week prior to and during cranial RT (60 Gy in 30 fractions, weeks 2-7). Patients with stable or responsive disease at week 18 received an additional 4 weeks of suramin (weeks 19-22). The median survival for suramin-treated patients was 11.6 months, with 1-year and 18-month survival rates of 49% (95% confidence interval [CI], 36%-62%) and 18% (95% CI, 8%-28%), respectively. Overall, 55% of the patients (30/55) had greater than grade 2 toxicity at least possibly related to suramin therapy. Two patients died of possibly related neurologic events (i.e., stroke, elevated intracranial pressure). Otherwise, toxicities were generally transient and self-limited. Administration of suramin using an intermittent fixed-dosing regimen during cranial RT was generally well tolerated. However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalNeuro-Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Suramin
Glioblastoma
Radiotherapy
Survival
Intercellular Signaling Peptides and Proteins
Confidence Intervals
Safety
Karnofsky Performance Status
Central Nervous System Neoplasms
Intracranial Hypertension
Growth Factor Receptors
Angiogenesis Inducing Agents
Brain Neoplasms
Glioma
Nervous System
Therapeutics
Survival Rate
Stroke
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Suramin and radiotherapy in newly diagnosed glioblastoma : Phase 2 NABTT CNS Consortium study. / Laterra, John J; Grossman, Stuart A; Carson, Kathryn Anne; Lesser, Glenn J.; Hochberg, Fred H.; Gilbert, Mark R.

In: Neuro-Oncology, Vol. 6, No. 1, 01.2004, p. 15-20.

Research output: Contribution to journalArticle

@article{d3f239af90e14722a344cb5fda34789d,
title = "Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study",
abstract = "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance. The safety and benefits of combining inhibitors of angiogenesis and growth factors with cytotoxic therapies in patients with neoplasms of the central nervous system remain unclear. The objectives of this phase 2 study were to determine the safety of administering suramin with standard cranial radiotherapy (RT) and to estimate survival using this approach in patients with newly diagnosed glioblastoma multiforme (GBM). Fifty-five patients with newly diagnosed GBM (Karnofsky performance status ≥60) were enrolled in this multicenter phase 2 study. Patients received suramin by a conventional intermittent fixed-dosing regimen for 1 week prior to and during cranial RT (60 Gy in 30 fractions, weeks 2-7). Patients with stable or responsive disease at week 18 received an additional 4 weeks of suramin (weeks 19-22). The median survival for suramin-treated patients was 11.6 months, with 1-year and 18-month survival rates of 49{\%} (95{\%} confidence interval [CI], 36{\%}-62{\%}) and 18{\%} (95{\%} CI, 8{\%}-28{\%}), respectively. Overall, 55{\%} of the patients (30/55) had greater than grade 2 toxicity at least possibly related to suramin therapy. Two patients died of possibly related neurologic events (i.e., stroke, elevated intracranial pressure). Otherwise, toxicities were generally transient and self-limited. Administration of suramin using an intermittent fixed-dosing regimen during cranial RT was generally well tolerated. However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations.",
author = "Laterra, {John J} and Grossman, {Stuart A} and Carson, {Kathryn Anne} and Lesser, {Glenn J.} and Hochberg, {Fred H.} and Gilbert, {Mark R.}",
year = "2004",
month = "1",
doi = "10.1215/S1152851703000127",
language = "English (US)",
volume = "6",
pages = "15--20",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Suramin and radiotherapy in newly diagnosed glioblastoma

T2 - Phase 2 NABTT CNS Consortium study

AU - Laterra, John J

AU - Grossman, Stuart A

AU - Carson, Kathryn Anne

AU - Lesser, Glenn J.

AU - Hochberg, Fred H.

AU - Gilbert, Mark R.

PY - 2004/1

Y1 - 2004/1

N2 - Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance. The safety and benefits of combining inhibitors of angiogenesis and growth factors with cytotoxic therapies in patients with neoplasms of the central nervous system remain unclear. The objectives of this phase 2 study were to determine the safety of administering suramin with standard cranial radiotherapy (RT) and to estimate survival using this approach in patients with newly diagnosed glioblastoma multiforme (GBM). Fifty-five patients with newly diagnosed GBM (Karnofsky performance status ≥60) were enrolled in this multicenter phase 2 study. Patients received suramin by a conventional intermittent fixed-dosing regimen for 1 week prior to and during cranial RT (60 Gy in 30 fractions, weeks 2-7). Patients with stable or responsive disease at week 18 received an additional 4 weeks of suramin (weeks 19-22). The median survival for suramin-treated patients was 11.6 months, with 1-year and 18-month survival rates of 49% (95% confidence interval [CI], 36%-62%) and 18% (95% CI, 8%-28%), respectively. Overall, 55% of the patients (30/55) had greater than grade 2 toxicity at least possibly related to suramin therapy. Two patients died of possibly related neurologic events (i.e., stroke, elevated intracranial pressure). Otherwise, toxicities were generally transient and self-limited. Administration of suramin using an intermittent fixed-dosing regimen during cranial RT was generally well tolerated. However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations.

AB - Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance. The safety and benefits of combining inhibitors of angiogenesis and growth factors with cytotoxic therapies in patients with neoplasms of the central nervous system remain unclear. The objectives of this phase 2 study were to determine the safety of administering suramin with standard cranial radiotherapy (RT) and to estimate survival using this approach in patients with newly diagnosed glioblastoma multiforme (GBM). Fifty-five patients with newly diagnosed GBM (Karnofsky performance status ≥60) were enrolled in this multicenter phase 2 study. Patients received suramin by a conventional intermittent fixed-dosing regimen for 1 week prior to and during cranial RT (60 Gy in 30 fractions, weeks 2-7). Patients with stable or responsive disease at week 18 received an additional 4 weeks of suramin (weeks 19-22). The median survival for suramin-treated patients was 11.6 months, with 1-year and 18-month survival rates of 49% (95% confidence interval [CI], 36%-62%) and 18% (95% CI, 8%-28%), respectively. Overall, 55% of the patients (30/55) had greater than grade 2 toxicity at least possibly related to suramin therapy. Two patients died of possibly related neurologic events (i.e., stroke, elevated intracranial pressure). Otherwise, toxicities were generally transient and self-limited. Administration of suramin using an intermittent fixed-dosing regimen during cranial RT was generally well tolerated. However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations.

UR - http://www.scopus.com/inward/record.url?scp=0942277090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942277090&partnerID=8YFLogxK

U2 - 10.1215/S1152851703000127

DO - 10.1215/S1152851703000127

M3 - Article

C2 - 14769135

AN - SCOPUS:0942277090

VL - 6

SP - 15

EP - 20

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -